Tiragolumab Impresses in Multiple Trials
Unknown authors
Abstract
The TIGIT inhibitor tiragolumab, alone or in combination with the PD-L1 inhibitor atezolizumab, may be effective against solid cancers. In phase I and II trials, the agent achieved statistically significant results in multiple solid malignancies-most notably non-small cell lung cancer.
Topics & Concepts
AtezolizumabTIGITSolid tumorMedicineLung cancerClinical trialCancerCancer researchOncologyPharmacologyInternal medicineImmunotherapyPembrolizumabCancer Immunotherapy and BiomarkersCancer Research and TreatmentsImmunotherapy and Immune Responses